The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

+ Details

Name:	us-gaap_ShareBasedCompensation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Description of award terms as to how many shares or portion of an award are no longer contingent on satisfaction of either a service condition, market condition or a performance condition, thereby giving the employee the legal right to convert the award to shares, to sell the shares, and be entitled to the cash proceeds of such sale. For example, vesting may be expressed as being 25 percent of the shares under option on each anniversary of the grant date.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

+ Details

Name:	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Gross number of share options (or share units) granted during the period.

+ References

No definition available.

+ Details

Name:	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.

+ References

No definition available.

+ Details

Name:	us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
Namespace Prefix:	us-gaap_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_PlanNameAxis=atos_Plan2010Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_BoardOfDirectorsChairmanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ChiefFinancialOfficerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

STOCK BASED COMPENSATION (Details Narrative) - USD ($)		3 Months Ended		6 Months Ended
STOCK BASED COMPENSATION (Details Narrative) - USD ($)	Jun. 27, 2018	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018
Stock-based compensation expense		$ 179,050	$ 181,408	$ 1,557,163
Number of options granted				611,668
Option exercise price (in dollars per share)				$ 2.39
2010 Plan [Member]
Option exercise price (in dollars per share)		$ 2.38
Description of vesting rights		<p><font style="font: 10pt Times New Roman, Times, Serif">Twenty-five percent of the options have vested as of the grant date, 50% of the options will vest quarterly over two years, and the remaining 25% will vest upon achievement of certain milestones related to clinical trial progress.</font></p>
2010 Plan [Member] \| Dr. Steven C. Quay [Member]
Number of options granted	2,300,000
2010 Plan [Member] \| Kyle Guse [Member]
Number of options granted	700,000